FDA labeling for EGRIFTA WR states that tesamorelin is indicated for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, while also noting that it is not indicated for weight-loss management and that long-term cardiovascular safety has not been established. For a research comparison article, Tesamorelin gives useful context: it shows that the GHRH analog category is not limited to CJC-1295 and Sermorelin
These peptides are not intended for human consumption, medical treatment, veterinary applications, or any use outside controlled research environments
doi: 10.1021/bi00892a002 15 DatsenkoK
It is not intended for human consumption, diagnostic, or therapeutic use
Serious reactions are rare but possible
Lot Traceability and Public COA Library Every vial carries a lot identifier printed on the label that ties to one complete analytical record - HPLC, LC-MS, and endotoxin